Romiplostim reverts the thrombocytopenia in den--gue hemorrhagic fever
To the Editor: First-genera--tion thrombopoietic agents were recombinant forms of human thrombopoietin (TPO), but their development was discontinued due to the onset of neutralizing autoantibodies cross-reacting with endogenous TPO. Second-gen--eration thrombopoiesis-stimulat--ing molecules (romiplostim and eltrombopag), have completed phase III trials in primary im--mune thrombocytopenia, whereas phase II and III trials are ongoing in other conditions characterized by thrombocytopenia.
1 Dengue is the most prevalent arthropodborne virus affecting humans to--day causing a spectrum of disease, ranging from a mild febrile illness to a life-threatening dengue hem--orrhagic fever (DHF) . 2 The main hematological findings of dengue are leukopenia, thrombocytopenia, lymphocytopenia and the presence of atypical lymphocytes; in DHF, the thrombocytopenia is more pro--longed, while the other hematolog--ical abnormalities are not; 3 DHF is endemic in México. 4, 5 Multiple myeloma was identi--fied in November 2007 in a 54-year old woman; she was initially treated with thalidomide/dexamethasone /bortezomib until achieving a very good partial response and then autografted using high-dose mel--phalan.
6 After the autograft, she was given thalidomide, 100 mg/ day. Thirty-six months later she developed headache, gastrointesti--nal symptoms, retro-orbital pain, myalgia, joint pain, petechiae, pur--pura and gum bleeding. The blood cell count disclosed thrombocy--topenia (2×10 9 /L), leukopenia (0.7×10 9 /L) and granulocytopenia (0.05×10 9 /L); dengue virus anti--gen and IgM antibodies were pres--ent; the bone marrow had hypo--plasia and no evidence of myeloma was found. The patient was treated with intravenous hydrocortisone (300 mg/day) and subcutaneous filgrastim (300 ug/day), with the neutropenia resolving 4 days later. The thrombocytopenia did not re--solve and was later treated unsuc--cessfully with oprelvekin and plate--let transfusions. Fifty-two days after the thrombocytopenia en--sued, subcutaneous romiplostim (4 ug/Kg/week) was started, and the platelet count increased promptly (Figure 1) . The patient remained with >100×10 9 /L platelets, 230 days after starting romiplostim.
Treatment of dengue fever, whether in its uncomplicated form or with hemorrhagic manifestations remains symptomatic. Steroids have proved useful when DHF compli--cates with septic shock 7 and even though thrombocytopenia resolves spontaneously frequently, may be prolonged in certain circumstanc--es.
8 There are reports of anti-D immune globulin in DHF cases with severe and prolonged throm--bocytopenia 9 but to the best of our knowledge, this is the first case of DHF in which romiplostim has been successfully used. An immune mechanism of thrombocytopenia due to increased platelet destruc--tion appears to be operative in pa--tients with DHF; 9 however, in the case that we are reporting, the previ--ous stem cell transplant and the use of thalidomide led to a hypoplastic marrow which most likely was un--able to compensate the peripheral platelet destruction.
Romiplostim has been shown to be effective in ameliorating throm--bocytopenia in patients with chronic idiopathic thrombocytopenic pur--pura and other thrombocytopenic conditions. 10, 11 Its usefulness in this case may stem from the combined origin of the thrombocytopenia, on one hand the platelet destruction caused by the dengue virus and on the other a hyploplastic marrow derived not only from the viral in--fection, but also from the previous stem cell allograft and the chronic use of thalidomide. Standard treatment is not well estab--lished and anthracycline containing combination chemotherapy (CHOP) had less than 30% survival at 5 years in localized disease. 5 We report a case of extranodal NK/T cell lympho--ma, nasal type, treated initially with CHOP as a large cell lymphoma and then with high-dose methotrexate, L-asparaginase and dexamethasone as part of a multicenter phase II clini--cal trial (GELA-GOELAMS) for extranodal NK/T cell lymphoma.
A 34-year-old man, a welder by profession for 17 years, was seen in September 2008 for a right unilateral nasal obstruction associated with re--current epistaxis (Figures 1,2 ). There were no associated B symptoms and performance status was 1. Anterior rhinoscopy revealed a right nasal cavity ulcerated mass with bleeding on touch. There was no other abnor--mal finding on physical examination with no peripheral adenopathy or hepatosplenomegaly. The diagnosis of NHL was established after several attempts at biopsy due to secondary infection and necrosis. The pathology was reported as consistent with large cell NHL and available immunohis--tochemistry showed lack of expres--sion of CD20, CD3, and cytokeratin. Patient was staged as Ann Arbor stage IEA with no poor prognostic factors according to the International Prognostic Index. The patient was started on CHOP chemotherapy but after two cycles, he had a poor response with a significant increase of the initial lesion and extension to the right upper lip. A repeat biopsy showed a diagnosis of extranodal NK/T-cell lymphoma, nasal type with EBV+.
The patient was switched to combined treatment with metho--trexate 3g /m2 on day 1, L-asparagi nase 6000U/m 2 on day 2, 4, 6 and 8 with dexamethasone 40 mg day 1 to day 4 on 21 days cycle for a total of three cycles. The patient responded nicely and the tumor regressed after the first cycle. The patient achieved a complete clinical response after a second cycle (Figure 3) . One month after the third cycle, he started ir--radiation, 30 Gy to the initial site of the disease. At the time of last follow up at 24 months, he was in complete remission (Figure 4) . In conclucion, extranodal NK/Tcell lymphoma nasal type is a rare entity. Diagnosis may be difficult without an appropriate panel of im--munohistochemistry that may not be available in all hospitals, especially the detection of cytoplasmic expres--sion (CD3ε), EBV expression and molecular biology techniques. Cases with clinical suspicion of extranodal NK/T-cell lymphoma should have a full panel of immunohistochemis--try from a tertiary referral center if needed. Conventional anthracyclinbased thereapy (CHOP) has a poor outcome. This could be related to the overexpression of PGP (multidrug resistance) by NK/T tumor cells.
6 Chemosensitivity to L-aspar--aginase and high-dose methotrexate has encouraging results and should be tested in future prospective stud--ies.
7-8 Our patient had 17 years of occupational exposure to iron dusts and galvanized metals (welding) that may had contributed to the de--velopment of this type of NHL In our patient .
